Novo Nordisk shares rose Friday after the FDA granted accelerated approval for Wegovy to treat liver fibrosis in adults, ...

Major U.S. equities indexes were little changed Monday morning, ahead of retail sector earnings reports and comments from ...

Expanded approval of Wegovy was based on results from the Phase III ESSENCE trial (NCT04822181), which demonstrated ...

The FDA has approved Novo Nordisk’s Wegovy to treat metabolic associated steatohepatitis, or MASH, in adults who have excessive scar tissue in the liver. MASH is a serious liver condition linked to ...

CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest news on Novo Nordisk, what new FDA approval on its ...

A total of 237 estimates from 47 studies covering more than 1.5 million cases of any ethnicity were included in the study.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of hepatic fibrosis, yet its prevalence in asymptomatic ...

Using a novel 3D culture system, an international team of researchers have created the first vascularized liver organoid.

Novo Nordisk share price rose nearly 5% on August 18, 2025. The hike came after the US Food and Drug Administration granted ...

It’s been more than a year since Browns great Bernie Kosar announced he was placed on a liver transplant list.

Novo Nordisk stock gains as FDA expands Wegovy use, while Ozempic price cut aims to boost access and defend market share.

With a new endorsement from the FDA, Novo Nordisk’s Wegovy has picked up its third indication and become the second drug ...